Rogerd Tung News Today : Breaking News, Live Updates & Top Stories | Vimarsana

StockNews com Initiates Coverage on Concert Pharmaceuticals (NASDAQ:CNCE)

StockNews.com initiated coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) in a report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Several other equities analysts also recently weighed in on the company. JMP Securities downgraded Concert Pharmaceuticals to a market perform rating in a research report […]

Rogerd tungNancy stuartConcert pharmaceuticals incNews ratings for concert pharmaceuticals dailySecurities exchange commissionJefferies financial groupConcert pharmaceuticals stock performanceConcert pharmaceuticalsNantahala capital managementMillennium managementVanguard group incGet ratingFinancial groupTruist financialExchange commissionCapital management

Form SC 14D9 CONCERT PHARMACEUTICALS, Filed by: CONCERT PHARMACEUTICALS, INC

Form SC 14D9 CONCERT PHARMACEUTICALS, Filed by: CONCERT PHARMACEUTICALS, INC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkNew jerseyState of delawareJohnm mutkoskiRichardh aldrichRoger tungThomasg auchincloss jrNancy stewartPeter barton huttSun pharmaWilfrede jaegerThomas auchinclossRogerd tungMarca beckerChristine van heek

Form SC14D9C CONCERT PHARMACEUTICALS, Filed by: CONCERT PHARMACEUTICALS, INC

Form SC14D9C CONCERT PHARMACEUTICALS, Filed by: CONCERT PHARMACEUTICALS, INC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohnm mutkoskiTeviak pollardRogerd tungAndrewh goodmanName of subject companyConcert pharmaceuticals incGoodwin procterSubject companyPersons filing statementCurrent reportConcert pharmaceuticals

Concert Pharmaceuticals (NASDAQ:CNCE) Releases Quarterly Earnings Results, Misses Estimates By $0 10 EPS

Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) issued its quarterly earnings results on Thursday. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.10), MarketWatch Earnings reports. Concert Pharmaceuticals had a negative return on equity of 69.59% and a negative net margin of 245.72%. During the same […]

Rogerd tungSecurities exchange commissionConcert pharmaceuticalsZacks investment researchDe shaw coConcert pharmaceuticals company profile get ratingCubist systematic strategiesConcert pharmaceuticals incEarnings history for concert pharmaceuticalsGet ratingMarketwatch earningsExchange commissionSystematic strategiesTwo sigma advisersSigma advisersPharmaceuticals company profile

Concert Pharmaceuticals (NASDAQ:CNCE) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small […]

United statesRogerd tungConcert pharmaceuticalsNewedge wealthZacks investment researchBlackrock incAmerica corpConcert pharmaceuticals company profile get ratingAcadian asset managementConcert pharmaceuticals incMillennium managementGet ratingAsset managementPharmaceuticals company profileNasdaq cnce